Business Wire

Adva Network Security Layer 2 encryption technology achieves German BSI approval

Share

Adva Network Security today announced that its flagship 10Gbit/s edge solution with ConnectGuard Ethernet encryption has been approved for the transmission of classified data by the German Federal Office for Information Security (BSI). With BSI clearance to transport VS-NfD and NATO RESTRICTED (NR) information, the FSP 150-XG118Pro (CSH) enables customers to deploy a secure network access device guaranteed to meet stringent regulatory requirements. With comprehensive demarcation capabilities and an optional server blade, the device offers several additional advantages, such as precise synchronization and NFV hosting. Its approval by the BSI will be a major boost for customers with high security standards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005865/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BSI approval for Adva Network Security’s 10G Ethernet device will prove key for data protection at the network edge. (Photo: Business Wire)

“We work with public authorities, critical infrastructure operators and enterprises whose networks are particularly threatened by cyberattacks as they often contain the most sensitive and mission-critical data. Today’s announcement will be big news for them. Now it’s possible to securely harness a 10Gbit/s edge solution with a unique set of capabilities such as next-generation timing delivery, network virtualization and comprehensive service assurance,” said Michael Roth, GM of Adva Network Security. “We were the first in the industry to attain BSI clearance for our Layer 1 technology. Now it’s the turn of our Layer 2 solution. As a qualification, BSI approval is one of the most challenging in the industry. Achieving it not only highlights the power of the protection offered by our device, but also our commitment to security in all our business processes.”

The FSP 150-XG118Pro (CSH) is a compact, power-efficient solution for network access that combines 10Gbit/s Carrier Ethernet, IP service demarcation, and aggregation with a rich set of programmability and synchronization features. It offers robust network protection with dynamic key exchange and hardware tamper protection for the most sensitive data, and is also ready to support quantum-safe key exchange. The approval of the FSP 150-XG118Pro (CSH) by the BSI follows certification for the ADVA FSP 3000 Layer 1 encryption solution, which is already playing a key role in the transport of EU- and NATO-classified data. Customers can now have complete peace of mind that their data at both Layers 1 and 2 is secured to the most rigorous standards and compliance requirements.

“Public authorities and critical infrastructure use wide area networks and are looking to apply end-to-end encryption to standard MEF services that meet the strictest industry standards. Now our FSP 150-XG118Pro (CSH) offers a solution that ensures BSI-approved security for metro networks along with the key capabilities needed to deliver tomorrow’s services,” commented Uli Schlegel, senior director of product line management at Adva Network Security. “Our FSP 150-XG118Pro (CSH) meets tight constraints for latency, power and size. It includes a rich set of operational features and supports a pluggable server module for hosting virtualized network functions. With BSI approval, it’s the ultimate choice for rapid innovation and security at the network edge.”

Further information on the FSP 150-XG118Pro (CSH) is available in this video: https://youtu.be/6w7Z3CLBRFE.

About Adva Network Security
Adva Network Security has built a fierce reputation for protecting packet optical networks. We pioneered low-latency, multi-layer encryption solutions that are right now safeguarding data in motion for many mission-critical applications. Our ConnectGuardTM security technology is even combating tomorrow’s quantum security threats. Built by the industry’s leading security experts, our German-based organization helps organizations and government agencies security-harden their networks to ensure critical infrastructure is protected against cyber threats. Our development and manufacturing processes, as well as our security solutions, have been approved and certified by leading governmental security agencies. For more information on how we can help you, please visit www.advasecurity.com.

Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye